Abstract:Mesenchymal stem cells (MSCs) possess inherent tropism to malignant cells and home to disseminated tumor foci, making MSCs an ideal candidate as targeting vehicle for drug delivery. Our previously synthesized doxorubicin (DOX)-polymer conjugates (PPCD) modified by RGD (RGD-PPCD) harness tremendous potential with active targeting and sustained release. To further enhance the conjugates penetrability and tumor tracking capability, MSCs-mediated RGD-/PPCD delivery system was created and constructed by spontaneous incorporation. The present study investigated the anti-tumor activities of MSCs loaded with RGD-/PPCD (MSCsRGD-/PPCD), compared to their corresponding RGD-/PPCD and MSCs loaded with DOX (MSCsDOX), especially. MTT assay demonstrated that although RGD-/PPCD could inhibit MSCs proliferation, there was no direct cytotoxicity to MSCs. After optimization, maximum drug loading amount was obtained by incubating MSCs for 12 h at the drug concentration of 50 μg/mL (DOX-equiv.). Further drug release and intracellular retention proved that, compared to MSCsDOX, MSCsRGD-/PPCD delayed the release peak to 12–48 h with continuous drug liberation more than 5 days, declaring the time dependent release behavior and lasting stability of conjugates in MSCs for cell-directed tumoritropic delivery. For MSCsRGD-/PPCD, intrinsic cell functions without compromise were verified by cell cycle analysis, transmigration assay and tumor penetration, while MSCsDOX showed observable but not significant suppression. As for in vivo studies, among all groups, mice intracranially administrated with MSCsPPCD and MSCsRGD-PPCD acquired the longest survival time with median being 41 and 45 days, and increased life span with 34% and 46.8% versus RGD-PPCD treatment group, respectively. Additionally, MSCsRGD-/PPCD exhibited more extensive penetration and enhanced tumor cell apoptosis than MSCsDOX. As proof of the concept, without any genetic manipulation and chemical modification, a novel modality integrating MSCs and DOX-polymer conjugates could vigorously ship therapeutics for efficient glioma therapy.

Mesenchymal Stem Cells Loaded with Paclitaxel-Poly(lactic-co-glycolic Acid) Nanoparticles for Glioma-Targeting Therapy

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme

Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy.

Mesenchymal stem cells transporting black phosphorus-based biocompatible nanospheres: Active trojan horse for enhanced photothermal cancer therapy

Glioma Therapy Using Tumor Homing and Penetrating Peptide-Functionalized Peg-Pla Nanoparticles Loaded with Paclitaxel

PEG-co-PCL Nanoparticles Modified with MMP-2/9 Activatable Low Molecular Weight Protamine for Enhanced Targeted Glioblastoma Therapy

Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer

Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel.

PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.

Mesenchymal Stem Cells As Therapeutic Agents and in Gene Delivery for the Treatment of Glioma

Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles

The Influence of the Penetrating Peptide Irgd on the Effect of Paclitaxel-Loaded MT1-AF7p-conjugated Nanoparticles on Glioma Cells

Self-Assembled Tumor-Penetrating Peptide-Modified Poly(l-γ-glutamylglutamine)–Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma

Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy.

Substance P-modified Human Serum Albumin Nanoparticles Loaded with Paclitaxel for Targeted Therapy of Glioma

Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma

RVG29-modified Docetaxel-Loaded Nanoparticles for Brain-Targeted Glioma Therapy

Combination chemotherapy via poloxamer 188 surface-modified PLGA nanoparticles that traverse the blood-brain-barrier in a glioblastoma model

Enhanced Antiglioblastoma Efficacy of Neovasculature and Glioma Cells Dual Targeted Nanoparticles